CD274 and melanoma: For instance, overall response rate for pembrolizumab in advanced melanoma is 32.9%24 The variability in patients’ response highlights the need for better mechanistic understanding of the underlying mutations and improved accuracy of predictive biomarkers for ICI outcomes, such as tumor mutation burden (TMB), PD-L1 expression, and microsatellite instability (MSI)25–29.